Background Dehydroepiandrosterone sulphate (DHEAS) is a steroid that is increasingly being recognized as a potential drug of abuse in many countries. This is due to its reputation as a hormone that may be able to retard the ageing process.
Introduction
Dehydroepiandrosterone sulphate (DHEAS) is a 19carbon steroid, which is a precursor for androgens and oestrogens. It is the most abundant circulating hormone in the body. Serum concentrations of DHEAS peak at the age of 25 years and then decline steadily over the following decades. 1 Dehydroepiandrosterone (DHEA) and DHEAS are synthesized and excreted primarily by the zona reticularis of the adrenal cortex. The adrenal gland is the sole source of these steroids in women, whereas in men the testes secrete 5% of DHEAS and 10--25% of DHEA. 2, 3 DHEA and DHEAS serve as the precursors to approximately 50% of androgens in adult men, 75% of active oestrogens in premenopausal women and 100% of active oestrogens in postmenopausal women. 2 In humans, DHEA is released into the circulation as DHEAS, with 99% of circulating DHEA being in the sulphate form. The half-life of DHEA is estimated to be 15--30 min with a metabolic clearance rate (MCR) of 1388 mL/min. The half-life of DHEAS is much longer at 7--10 h and the MCR is 4.2--17 mL/min. 1 Raised levels of DHEAS are found in the plasma of patients with adrenal tumours or with congenital adrenal hyperplasia. DHEAS may also be slightly elevated in patients with polycystic ovary syndrome, supporting an adrenal component to the virilization seen in this condition. 4 Serum concentrations of DHEAS serve as an early indicator for the onset of adrenarche. Very high concentrations of DHEAS in women are suggestive of a hormone-secreting adrenal tumour and DHEAS measurements are therefore commonly used in the di¡erential diagnosis of a virilized patient. Virilizing tumours of the ovary are associated with marked increases in serum testosterone but near normal DHEAS levels, while virilizing tumours of the adrenals secrete very large amounts of potent androgens as well as DHEAS. DHEAS is usually undetectable in adrenal insu⁄ciency or panhypopituitarism.
DHEAS has been advertised as a'fountain of youth' in that it appears to be the hormone that retards the ageing process in humans. 1 This has led to widespread uncontrolled use of DHEAS and DHEA in countries such as the USA, and it is now being abused in other countries around the world. 1 Methods currently used in hospital laboratories include, a competitive binding assay, 5 chemiluminescence immunoassays 6,7 and a coated tube radioimmunoassay. 8 There are drawbacks with these methods, for example turnaround time is slow and kits are expensive.
Other methods used to measure DHEAS in human serum or plasma include enzyme immunoassay, 9 gas liquid chromatography, 10 gas chromatography with ion trap mass spectrometry 11 and liquid chromatography--mass spectrometry. 12 However, not many hospitals have access to gas liquid chromatography in their laboratories and it is normally used for more specialized analysis, for example, metabolic biochemistry or toxicology. The use of liquid chromatography-tandem mass spectrometry (LC--MS/MS) to measure DHEAS would improve the speci¢city and signi¢cantly reduce the turn around time of the analysis as incubation steps are not necessary. LC--MS/MS has been used to great e¡ect in our centre and is an essential piece of equipment for the analysis of many drugs and steroids, including cyclosporin, 13 tacrolimus, 14 voriconazole, 15 prednisolone 16 and urinary-free cortisol. 17 
Materials and method
Internal standard, standards, quality control and patient samples Deuterated (d2) DHEAS (QMx Laboratories Limited, Thaxted, UK) was used as internal standard. The working concentration used was 2 mmol/L in methanol. Standards were prepared by spiking DHEAS (Sigma, Poole, UK) from a 13.3 mmol/L solution of DHEAS in methanol that was kept at À301C into phosphate bu¡er solution (PBS) pH 7.4, to give concentrations ranging from 0 to 20 mmol/L. Aliquots were frozen and a new set was used for each batch. Quality control (QC) solutions were prepared in a similar fashion but from a separate highly concentrated stock containing 14.85 mmol/L of DHEAS in methanol, which was kept frozen. They were then diluted in PBS as above to give concentrations ranging from 1 to 18 mmol/L.
We also determined the suitability of commercially available QC for use in the assay (Bio-Rad Labs LTD, Bio-Rad House, Hemel Hempstead, UK) and analysed external quality assurance samples (United Kingdom National External QualityAssurance Scheme [UK NEQAS], Wolfson EQA Laboratory, Birmingham, UK). Local ethical committee approval was given for the development of the DHEAS assay.
Sample preparation
In all, 20 mL of serum sample, standard or QC was placed in a 96-deep well block followed by 40 mL of 0.1mol/L zinc sulphate (VWR International Ltd, Poole, UK). Following a brief vortex (10 s), 100 mL of internal standard (2 mmol/L) and 100 mL of 50:50 methanol:acetonitrile were added. The plate was then thermo-sealed, vortexed for 60 s and then centrifuged at 8000 g for 5 min. The plate was transferred to the auto-sampler for analysis and 10 mL of the supernatant was injected into the liquid chromatography system.
High-performance liquid chromatography
The chromatography was performed using a Waterst 2795 Alliance HT LC system (Waters Ltd, Watford, UK). The analytical column was a 20 Â2.0 mm, 2 mm Mercury Fusion-RP column, ¢tted with a 3.0 Â2.0 mm SecurityGuardt column (Phenomenex s , Maccles¢eld, UK).
The mobile phases used were A (water containing 2 mmol/L ammonium acetate with 0.1% [v/v] formic acid) and B (methanol containing 2 mmol/L ammonium acetate with 0.1% [v/v] formic acid). The gradient consisted of 55% B for 1.9 min, then a step up to 100% B for 0.5 min, followed by a step down to 55% B for 1.6 min. The £ow rate was maintained at 0.4 mL/min and the column was operated at 501C in a column oven to reduce viscosity and hence back pressure.
Mass spectrometry
A Micromass Quattrot tandem mass spectrometer (Micromass, Manchester, UK) with a Z spray ion source was coupled to the HPLC system. MassLynx NT 3.5 software (provided with the mass spectrometer) was used for system control and the MassLynx QuanLynx programme allowed data processing. To produce a standard curve the software used integration of the area under the chromatogram, 1/x weighting and linear least-squares regression. The mass spectrometer was operated in electrospray negative mode; the capillary was kept at 1kVand the source temperature maintained at 1401C. The gas £ow was 631 L/h and the desolvation temperature was kept at 3501C. The tuning of the mass spectrometer was carried out with a 2.56 mmol/L solution of DHEAS and a 2.55 mmol/L solution of d2-DHEAS in methanol. The cone and collision energies were 40 V and 31eV, respectively. The responses were monitored in a multiple reaction-monitoring (MRM) mode with a dwell time of 0.25 s.
Validation
Published criteria were used to perform the validation of the method. 18 Accuracy, imprecision, recovery, linearity, speci¢city and stability of the method were determined, as well as the matrix-induced ion suppression e¡ects.
Ion suppression
Ion suppression is a matrix-associated phenomenon caused by compounds that coelute with the compound of interest and compete with ionization in the mass spectrometer source. To investigate this, a 10 mmol/L solution of DHEAS in methanol was infused directly into the mass spectrometer. This allowed a constant signal in the speci¢c MRM channel for DHEAS. When an extracted serum sample was injected into the system via the LC system, ion suppression was seen as a reduction (410%) in the speci¢c signal for DHEAS.
Accuracy and imprecision
DHEAS QC samples were used to determine the intraassay imprecision. The samples were extracted and the four concentrations were analysed 15 times in the same analytical run. 18 The coe⁄cient of variation (CV) of the replicates was required to be less than 15% to be deemed acceptable. Bias was required to be less than 15% of the theoretical concentration. 18 Inter-assay imprecision was carried out by analysing the QC samples over a three-week period in 15 separate batches. The above procedures were also carried out on Bio-Rad Lyphocheck QC levels 1--3.
The lower limit of detection (LLoD) is de¢ned as the concentration of an analyte that gives a 3:1 signal-tonoise ratio. The lower limit of quantitation (LLoQ) was determined by analysing10 replicates of the in-house QC. The lowest concentration of DHEAS measurable with a CVof o20% and bias o20% was taken as the LLoQ. 18 
Linearity
To determine the linearity, a standard curve was constructed using a range of standards from 0 to 20 mmol/L. The range was considered to be linear if the correlation coe⁄cient value was greater than 0.99; 18 this was calculated by linear least-squares regression.
Recovery
The recovery of DHEAS need not be 100%, but the extent of recovery of DHEAS and of the internal standard should be consistent, precise and reproducible. 18 DHEAS was spiked into four patient samples to give additional concentrations of 4, 8 and 16 mmol/L. The recovery was determined by comparing the concentrations of DHEAS before and after the addition of these amounts of DHEAS.
Stability
To determine stability, samples with concentrations of 4, 8 and 12 mmol/L were subjected to ¢ve freeze--thaw cycles and ¢ve days at room temperature. If samples were to be considered stable, their measured values were required to remain within 10% of the initial concentration. 18 To determine the stability of extracted samples, patient samples were extracted and analysed. The plate was resealed and then re-analysed 24 h later. The extract was considered stable if the DHEAS/d2-DHEAS peak area ratios were within 10% of the initial values. 18 To determine the stability of an extracted serum sample upon repeated injection, 10 mL of sample was injected repeatedly every 12 min for 17 h and the DHEAS/d2-DHEAS peak area ratios were observed for any decrease indicating a loss of sensitivity.
The stability of ¢ve patient samples upon storage at 4 and À201C over a ¢ve-day period was ascertained. Samples were deemed stable if concentration remained within 10% of the initial value.
Results
The transition identi¢ed for DHEAS was m/z 367.14 96.7 (Figure 1 ) and for d2-DHEAS m/z 369.1496.9 (Figure 2 ). Once the samples had been prepared, they gave a colourless and clear supernatant and chromatograms were produced, which did not have any interfering products present (Figure 3 ). Both DHEAS and d2-DHEAS had a retention time of1.5 min and the cycle time from injection to injection was 4 min. Ion suppression studies showed that there was no signi¢cant suppression in the region of 1.5 min where DHEAS elutes.
Standard curves were prepared by plotting DHEAS concentrations on the x-axis and DHEAS/d2-DHEAS peak area ratio on the y-axis (Figure 4 ). A linear curve was observed over the standard range. It was also reproducible between batches and the curve showed good correlation with the assigned standard values, with a correlation coe⁄cient value of 0.9992 and the least-squares regression line was y ¼ 0.1006x þ 0.0182.
The LLoD and LLoQ were both1 mmol/L. Mean recovery of the assay was103% (range 97--107%). QC samples remained stable for four freeze--thaw cycles and for two days at room temperature. The extract was stable during repeated injections over a 17-h period and the CV for peak area ratio over this time was 3% ( Figure 5 ). There was no signi¢cant change in extracted patient samples over the 24-h period and the change from baseline was 4.6%, showing that the extracts were stable over this time. Patient samples stored at 4 and À201C were considered stable, as the mean bias after ¢ve days was less than 10%. Table 1 shows the inter-and intraassay imprecision for the assay. The intra-and interassay imprecision for the in-house QC was acceptable at o11% and o8%, respectively. Table 2 shows the inter-and intraassay imprecision for the Bio-Rad Lyphocheck QC and this was also acceptable with CVs of o12% and o8%, respectively. However, the negative bias for the Bio-Rad Lyphocheck QC samples was greater than 15% for both levels 2 and 3. It must be taken into account that the designated values for each level of QC are a mean value determined by various methods.
Seventy-two patient samples were analysed by LC-MS/MS and compared with results obtained on the Nichols Advantage s Immunoassay analyser ( Figure 6 ). The LC-MS/MS analyser had an observed negative bias Figure 5 This figure shows the number of repeated injections over a 17-h period and the response (DHEAS/d2-DHEAS peak area ratio), given by the LC-MS/MS method for each injection, reflecting the stability of the method. 
Mean of DHEAS Difference between LC-MS/MS and the Nichols Advantage
Zero bias Figure 6 Bland-Altman plot comparing results obtained by LC-MS/MS and the Nichols Advantage s immunoassay analyser for 72 patient samples. Small sample volumes (20 mL) allowed measurements of DHEAS to be carried out on elderly or paediatric patient samples and should prove useful for the detection of congenital adrenal hyperplasia in the latter. 1 Steroids are generally measured using positive ionization mode. DHEAS, however, is easily measured in negative ionization mode, when the sulphate is used as the daughter fragment.
The d2-DHEAS is only 97% pure and this has caused a decrease in sensitivity for the detection of DHEAS at low concentrations (o1 mmol/L). The presence of d2-DHEAS in the internal standard caused an increase in area count for the zero standard and this has subsequently increased the LLoD. The sensitivity could be improved by utilizing a more puri¢ed form of d2-DHEAS, if it were available; however, the synthesis of d2-DHEAS is expensive and the reality of using relatively impure internal standard has caused no sig-ni¢cant problems.
Comparing the LC-MS/MS with the Nichols Advantage s immunoassay analyser by measuring UK NEQAS and patient samples on both has demonstrated that the dynamic range on the Nichols Advantage s assay is not very large and becomes non-linear above 16.7 mmol/L. Samples therefore require dilution at these higher concentrations. In comparison, the LC-MS/MS can measure DHEAS at high concentrations with no dilution of sample necessary, as can be shown by the excellent linearity of the standard curve (Figure 4 ) over the expected assay range.
The LC-MS/MS has potentially greater speci¢city for DHEAS compared with immunoassay techniques, which are currently used in many hospital laboratories. However, in our study there was very little di¡erence between the methods. The speci¢city is enhanced due to the chromatographic separation of analyte from interfering substances and the selectivity of the massto-charge ratio of DHEAS by the tandem mass spectrometer. Immunoassay techniques face di⁄culties with antibody speci¢city and interference (e.g. heterophilic antibodies and the saturation of antibodies in the presence of high concentrations of hormones), leading to samples requiring dilution. This increases the analytical variation of the assay, giving results that may not be accurate.
In conclusion, a rapid, sensitive assay on the LC-MS/ MS requiring minimal sample preparation and sample volume has been developed; the assay is also inexpensive to perform once the equipment is in place.
